Northeast Financial Consultants’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Northeast Financial Consultants’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-102	Closed	-$13K	–	165
2016 Q2	$13K	Buy	102 +50	+96%	+$5.54K	0.01%	150
2016 Q1	$6K	Hold	52	–	–	﹤0.01%	136
2015 Q4	$10K	Hold	52	–	–	0.01%	131
2015 Q3	$9K	Hold	52	–	–	﹤0.01%	140
2015 Q2	$33K	Hold	52	–	–	0.01%	150
2015 Q1	$27K	Hold	52	–	–	0.01%	141
2014 Q4	$28K	Hold	52	–	–	0.01%	132
2014 Q3	$79K	Hold	52	–	–	0.04%	134
2014 Q2	$71K	Buy	+52	New	+$60.3K	0.04%	128

Other funds holding VIRX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Northeast Financial Consultants's VIRX Position: Q3 2016 in Review

Northeast Financial Consultants sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2016, closing a stake of 102 shares — an estimated $13K sold.

Northeast Financial Consultants first reported a position in VIRX in Q2 2014 and held it in 9 quarters. The position peaked at $79K in Q3 2014. 40 funds tracked by Wall St. Rank hold VIRX as of Q3 2016.

Northeast Financial Consultants reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Northeast Financial Consultants sold 102 Viracta Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $13K.
Northeast Financial Consultants first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 9 quarters.
Northeast Financial Consultants's Viracta Therapeutics, Inc. Common Stock position peaked at $79K in Q3 2014.
40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Northeast Financial Consultants's 13F filing for Q3 2016, filed 8 Nov 2016.